The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
The grant will fund development of methods using the company's IsoLight system to study protein signaling pathways in single tumor cells.
The company's SpliceCore platform maps patient RNA sequencing data to a collection of over 5 million alternative splicing errors to pinpoint ones that cause disease.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
Acquired epilepsy is a form of the neurological disorder that results from other conditions such as stroke, infections, and traumatic brain injury.
The company aims to repurpose drugs by translating the mechanisms that allow hibernating animals to withstand the stresses of extended sleep.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.